Rotundic acid induces Cas3-MCF-7 cell apoptosis through the p53 pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Caspase-3 deficiency is linked to chemotherapy resistance in breast cancer.
• Rotundic acid (RA) is being investigated for its anti-cancer properties.
• Understanding RA's mechanism in apoptosis is crucial for therapeutic development.

Purpose of the Study:

• To investigate the functions and mechanisms of rotundic acid (RA) in inducing apoptosis in caspase-3-transfected MCF-7 human breast cancer cells (Cas3-MCF-7).
• To explore the role of p53 activation in RA-induced apoptosis.
• To assess the potential of RA as a novel therapeutic agent for breast cancer, particularly in cases of caspase-3 deficiency.

Main Methods:

• MTT assay to evaluate cell viability.
• Western blotting and fluorescence-activated cell sorting (FACS) to analyze apoptosis markers and pathways.
• Gene silencing of p53 to determine its role in RA-induced apoptosis.

Main Results:

• RA induced apoptosis more efficiently in Cas3-MCF-7 cells than in control MCF-7 cells.
• RA inhibited cell viability dose-dependently and induced apoptosis via caspase-3 activity.
• RA initiated apoptosis through p53 activation, as evidenced by western blotting and FACS.
• Silencing p53 reduced RA-induced caspase-3 activity and apoptosis in Cas3-MCF-7 cells.

Conclusions:

• Caspase-3 plays a critical role in rotundic acid-induced apoptosis.
• Caspase-3 deficiency may contribute to breast cancer chemotherapy resistance.
• Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to chemotherapy.
• RA holds potential as a novel drug, possibly combined with caspase-3 gene therapy, for treating human breast cancer with caspase-3 deficiency.